Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acefyl Cough is a multi-ingredient cough syrup developed and marketed by Nabiqasim Industries, primarily used for the symptomatic relief of cough and respiratory congestion. The formulation combines **acefylline piperazine**, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase and antagonizing adenosine receptors; **diphenhydramine hydrochloride**, a first-generation antihistamine that provides antitussive effects through H1 receptor antagonism; **ammonium chloride**, which serves as an expectorant to thin and loosen bronchial secretions; and **menthol**, which provides a cooling, soothing effect on the throat. It is commonly indicated for coughs associated with bronchitis, bronchial asthma, and the common cold.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acefylline piperazine + diphenhydramine + ammonium chloride + menthol.